Combined Antihistaminics Therapy in COVID 19 Patients

• Status: Not yet recruiting
• Trial end date: 2022-01-13
• Target enrollment: 0
• Participant gender: All

Summary

The use of antihistaminic medications could result in a significant immune modulation which may help in the treatment of cytokine storm of COVID-19.Thus, the aim of this study is to evaluate efficacy and safety of famotidine and loratadine combination in covid 19 treatment protocol.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ain Shams University
• Collaborator: Nasr City Insurance Hospital
• Treatments: Famotidine; Loratadine

Criteria

Inclusion Criteria:

1. Adult patients (>18 years old).

2. Confirmed COVId-19 infection with PCR.

3. Moderate covid patients who with Sp02 <92 %

4. CT chest infiltration more than 50 %

5. Presented to the hospital within 24 to 48 hours

6. CBC (WBCs may be normal or high or low with lymphocytopenia is present, decreased hemoglobin, neutrophilia with neutrophil/lymphocyte ratio > 3.1)

Exclusion Criteria:

1. Hepatic or renal failure: (Alanine transaminase or Aspartate transaminase >3 times above the normal limit)

2. History or evidence of long QT segment on Electrocardiogram,

3. Pregnancy or breast-feeding mother

4. Patient on mechanical ventilator.

5. Patient who received vaccine.

6. Patients receiving antidepressants, opioids, (e.g., anticonvulsants, clonazepam).